Insuman (insulin human)
- Region
- 🇪🇺 EU
- Active substance
- insulin human
- Company
- Sanofi-aventis Deutschland GmbH
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Wed 16 Oct 1996
- EU approval
- Fri 21 Feb 1997
- Application
- EMEA/H/C/000201
- ATC
- A10AB01;A10AC01
- Official record
- www.ema.europa.eu
Indication
Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Insulin Human Rechon Application withdrawn · Rechon Life Science AB
- 🇪🇺 Actraphane Authorised · Novo Nordisk A/S
- 🇪🇺 Mixtard Authorised · Novo Nordisk A/S
- 🇪🇺 Inpremzia Withdrawn · Baxter Holding B.V.
- 🇪🇺 Insulatard Authorised · Novo Nordisk A/S
- 🇪🇺 Protaphane Authorised · Novo Nordisk A/S
- 🇪🇺 Insulin Human Winthrop Withdrawn · sanofi-aventis Deutschland GmbH
- 🇪🇺 Solumarv Refused · Marvel Lifesciences Ltd
- 🇪🇺 Combimarv Application withdrawn · Marvel Life Sciences Ltd.
- 🇪🇺 Solumarv Application withdrawn · Marvel Life Sciences Ltd.
- 🇪🇺 Isomarv medium Application withdrawn · Marvel Life Sciences Ltd.
- 🇪🇺 Velosulin Withdrawn · Novo Nordisk A/S
Follow Insuman
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.